Benign Hematologic Conditions

Primary Immune Thrombocytopenia

Advarra IRB #H-44465/ Novartis #CVAY736Q12301 (VAYHIT2):: A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2) (pending IRB approval)